Mateon Therapeutics Inc (OTCMKTS:MATN)’s stock price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.19 and traded as high as $0.27. Mateon Therapeutics shares last traded at $0.27, with a volume of 100 shares changing hands.
MATN has been the topic of several research analyst reports. ValuEngine upgraded Mateon Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research downgraded Mateon Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th.
The business has a 50-day moving average of $0.25 and a 200 day moving average of $0.19.
Mateon Therapeutics (OTCMKTS:MATN) last posted its earnings results on Monday, August 19th. The biopharmaceutical company reported ($0.02) EPS for the quarter, hitting analysts’ consensus estimates of ($0.02). On average, analysts expect that Mateon Therapeutics Inc will post -0.06 EPS for the current fiscal year.
About Mateon Therapeutics (OTCMKTS:MATN)
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical, focuses on developing small molecule injectable drugs for the treatment of cancer. It is developing CA4P, an immuno-oncology agent that stimulates the immune system against the tumor; and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia.
Featured Article: What does a neutral rating on stocks mean?
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.